21-Chloro-6α, 9-difluoro-11β, 17-dihydroxy-16β-methylpregna-1, 4-diene-3,20-dione 17-propionate

Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
Halobetasol propionate, Ulobetasol propionate
API & Intermediates
KAPI2F05
66852-54-8
MFCD00866013
6918178
11109992
image-155171-Trimethyl(trifluoromethyl)silane_reagent.png
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
21-Chloro-6α, 9-difluoro-11β, 17-dihydroxy-16β-methylpregna-1, 4-diene-3,20-dione 17-propionate
C25H31ClF2O5
484.96
≥98%(HPLC)
White Solid
220-221°C
500mg,1g,10g,25g,50g,100g,500g and 1kg
2-8°C Refrigerator
Halobetasol propionate (also known as Ulobetasol propionate) is a super-potent corticosteroid with additional fluorine at the 6α position when compared with clobetasol 17-propionate, used as anti-inflammatory and dermatologic agent for the treatment of psoriasis. The additional fluorine in the 6α position further increases its topical anti-inflammatory and antiproliferative activities. Additionally, an ointment formulation in combination of halobetasol propionate and fusidic acid  for treatment of dermal conditions have been reported.
Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector. [1]
Spectrophotometric determination of clobetasol propionate, halobetasol propionate, quinagolide hydrochloride, through charge transfer complexation. [2]
A degradation product of halobetasol propionate: characterization and structure. [3]
Halobetasol versus clobetasol: A study of potency. [4]
Formulation and evaluation of novel combined halobetasol propionate and fusidic acid ointment. [5]
Topical corticosteroids in dermatology. [6]
Preliminary development studies of halobetasol propionate organogel for management of atopic dermatitis. [7]
Review Update on Topical Therapy for Psoriasis. [8]
References:
[1] J.C.Reepmeyer, J. Liq. Chromatogr. Related Technol., 2001, 24(5), pp 693-709.
[2] A.A.Mostafa, et al, J. Pharm. Biomed. Anal., 2002, 27(6), pp 889-899.
[3] G.Cravotto, et al, Steroids, 2007, 72(11-12), pp 787-791.
[4] S.Mohandas, et al, Indian J. Dermatol. Venereol. Leprol., 2009, 75(2), pp 186-187.
[5] C.M.Chakole, et al, Int. J. ChemTech. Res., 2009, 1(1), pp 103-116.
[6] A.B.Mehta, et al, Indian J. Dermatol. Venereol. Leprol., 2016, 82(4), pp 371-378.
[7] M.S.Lalan, et al, Int. J. Pharm. Sci. Res., 2017, 8(2), pp 775-783.
[8] V.M.Verallo-Rowell, et al, Curr. Dermatol. Rep., 2018, 7(1), pp 24-36.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Not a hazardous substance or mixture


2937220000
NONH for all modes of transport
Sales restrictions may apply.
1. Product Specification
For further information and support on USP Reference Standard, please go to the website of the issuing pharmacopoeia.
2. Safety Data Sheet
SDS issued by USP can be found here.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.